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To compare the survival of women with uterine papillary serous carcinoma (UPSC) and clear cell carcinoma (CC) to those
with grade 3 endometrioid uterine carcinoma (G3EC). Demographic, pathologic, treatment, and survival information were obtained
from the Surveillance, Epidemiology, and End Results Program from 1988 to 2001. Data were analysed using Kaplan–Meier and
Cox proportional hazards regression methods. Of 4180 women, 1473 had UPSC, 391 had CC, and 2316 had G3EC cancers.
Uterine papillary serous carcinoma and CC patients were older (median age: 70 years and 68 vs 66 years, respectively; Po0.0001)
and more likely to be black compared to G3EC (15 and 12% vs 7%; Po0.0001). A higher proportion of UPSC and CC patients
had stage III–IV disease compared to G3EC patients (52 and 36% vs 29%; Po0.0001). Uterine papillary serous carcinoma, CC and
G3EC patients represent 10, 3, and 15% of endometrial cancers but account for 39, 8, and 27% of cancer deaths, respectively. The
5-year disease-specific survivals for women with UPSC, CC and G3EC were 55, 68, and 77%, respectively (Po0.0001). The survival
differences between UPSC, CC and G3EC persist after controlling for stage I–II (74, 82, and 86%; Po0.0001) and stage III–IV disease
(33, 40, and 54; Po0.0001). On multivariate analysis, more favourable histology (G3EC), younger age, and earlier stage were
independent predictors of improved survival. Women with UPSC and CC of the uterus have a significantly poorer prognosis
compared to those with G3EC. These findings should be considered in the counselling, treating and designing of future trials for these
high-risk patients.
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Endometrial cancer is the most common gynecologic cancer
in the US. In total, 40880 new cases are projected in 2005,
with 7310 women dying from this disease (Jemal et al, 2005). The
majority of corpus cancers are early-stage, low-grade, endo-
metrioid tumours with a good prognosis. On the other hand,
uterine papillary serous carcinoma (UPSC), clear cell carcinomas
(CC), and grade 3 endometrioid carcinoma (G3EC) have been
identified as high-risk endometrial cancers and account for the
majority of uterine cancer deaths. Uterine papillary serous
carcinoma and CC histologies have also been identified as distinct
variants of endometrial cancer with a propensity for extrauterine
spread and poor prognosis (Clement and Young, 2004). Further-
more, previous studies have shown that women with G3EC have a
significant risk for nodal metastases at 28% (Creasman et al, 1987).
However, other authors have not been able to show a survival
difference between UPSC and CC compared to G3EC (Alektiar
et al, 2002; Creasman et al, 2004).
Over the past decade, some clinical trials have incorporated
UPSC, and CC while others have excluded these poor histologic
subtypes (Keys et al, 2004; Randell et al, 2006). This dichotomy
stems from the conflicting data in the current literature regarding
prognosis of high-risk endometrial tumours. Of the limited
published reports, most are based on small retrospective series
from single institutions that lack power to detect significant
differences. In this large population-based study, we report on the
outcomes of 4180 patients with UPSC, CC, and G3EC to determine
if there are significant prognostic differences between these
histologic cell types, and, if so, what clinico-pathologic prognostic
factors are responsible.
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sMATERIALS AND METHODS
After Institutional Review Board approval, 4180 women with high-
risk (UPSC, CC, and G3EC) endometrial cancers were extracted
from the Surveillance, Epidemiology and End Results (SEER)
database between 1988 and 2001. Additionally, 11014 patients with
grade 1 or 2 endometrioid (G1EC, G2EC) tumours were analysed
for demographic context. Data from the SEER database are
reported from twelve population-based registries that represent
approximately 14% of the US population: San Francisco-Oakland,
Connecticut, metropolitan Detroit, Hawaii, Iowa, New Mexico,
Seattle (Puget Sound), Utah, metropolitan Atlanta, Alaska, San
Jose-Monterey, and Los Angeles (Hankey et al, 1999).
Information including age at diagnosis, race, stage of disease,
histology, and adjuvant therapy were extracted and analysed. Race
was categorised as White, Black, Asian (Chinese, Japanese, Korean,
Vietnamese, or Filipina), or other race. Adjuvant radiotherapy was
categorised as either receiving or not receiving adjuvant radio-
therapy.
To analyse trends in the study cohort and to determine 5-year
disease-specific survival, w
2 tests and Kaplan–Meier analyses were
used to assess differences between UPSC vs CC vs G3EC. P-values
o0.05 were considered statistically significant, indicating statisti-
cally significant differences between the three histologic cell types.
The outcome of interest was death from endometrial cancer and
time to death was censored in women who died from causes other
than uterine cancer. The Cox proportional hazards model was used
to assess the significance of multiple variables simultaneously. All
data were analysed using Intercooled Stata (Version 8.0; Stata
Corporation, College Station, TX, USA) and SAS (Version 6.12;
SAS, Inc., Cary, NC, USA).
RESULTS
From 1988 to 2001, 4180 uterine cancer patients had high-risk
histologic cell types including 1473 with UPSC, 391 with CC, and
2316 with G3EC. The demographics of the study population are
presented in Table 1. The median age at diagnosis of the UPSC and
CC patients was significantly higher compared to those with G3EC
(70 years and 68 vs 66 years, respectively; Po0.0001). Blacks
comprised a significantly higher proportion of patients with UPSC
(15%) and CC (12%) compared to G3EC (7%; Po0.0001).
All patients in this study underwent a hysterectomy and surgical
staging procedure. Of the patients with stage I–II disease with
UPSC, CC, and G3EC, 55, 61 and 59% underwent lymph node
assessment, respectively. Of these patients, the median number of
nodes resected in those with UPSC, CC, and G3EC were 11, 11, and
13, respectively. Fifty-two percent of patients with UPSC had stage
III–IV disease compared to only 36 and 29% of those with CC and
G3EC, respectively (Po0.0001). Of women with UPSC, CC, and
G3EC, 39, 48, and 47% underwent adjuvant radiotherapy
(Po0.0001), respectively. However, we were unable to obtain
information regarding types of radiation, fields, or dosages.
Similarly, details on chemotherapy use or specific regimens were
not available.
Although patients with UPSC, CC, and G3EC represented only
10, 3, and 15% of endometrial cancers in our study population,
they accounted for 39, 8, and 27% of cancer deaths, respectively
(Figure 1). In the time interval studied, the percentage of patients
dying from their respective histologic cell type of endometrial
cancer (number of deaths for specific histology/number of patients
diagnosed with specific histology) were 34, 28, and 15% for UPSC,
Table 1 Patient and treatment data
UPSC
(n¼1473)
CC
(n¼391)
G3EC
(n¼2316) P-value
Median age (years) 70 68 66 Po0.0001
Race
White 1152 (78%) 298 (76%) 1976 (85%) Po0.0001
Black 213 (15%) 48 (12%) 164 (7%)
Asian 77 (5%) 33 (8%) 132 (6%)
Other 31 (2%) 12 (3%) 44 (2%)
Stage
a Po0.0001
I 533 (36%) 197 (50%) 1388 (60%)
II 171 (12%) 54 (14%) 252 (11%)
III 268 (18%) 71 (18%) 353 (15%)
IV 501 (34%) 69 (18%) 323 (14%)
aStage based on FIGO 1988. UPSC¼uterine papillary serous carcinoma. CC¼clear
cell carcinoma. G3EC¼grade 3 endometrioid carcinoma.
UPSC−Uterine papillary serous carcinoma
CC−Clear cell carcinoma
G1, G2EC – Grade 1 and 2 endometrioid carcinoma
G3EC – Grade 3 endometrioid carcinoma 
Proportion of corpus cancers
Proportion of corpus cancer deaths
UPSC
10%
UPSC
39%
Clear cell
3%
Clear cell
8%
72%
15%
G3EC
27%
G3EC
G1,G2EC
26%
G1,G2EC
Figure 1 Proportion of corpus cancers compared to proportion of
corpus cancer deaths by histologic cell type.
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sCC, and G3EC, respectively. Patients with UPSC and CC had a
significantly decreased 5-year disease-specific survival of 55 and
68% compared to 77% for G3EC (Figure 2). These survival trends
remain significant even when stratified by stage (Figure 3).
Patients with stage I–II UPSC, CC, and G3EC (n¼2595) had
survivals of 74, 82, and 86%, respectively, compared to 33, 40, and
53% in those with stage III–IV disease (n¼1585) (Po0.0001 for
stage I–II; Po0.0001 for stage III–IV). Of the 2118 women with
stage I disease, UPSC patients had a significantly worse survival
compared to CC and G3EC patients with survival rates at 80 vs 91%
and 92% for stage IB (P¼0.0001), and 66 vs 82% and 82% for stage
IC disease (P¼0.0017), respectively. However, we were unable to
demonstrate a statistical difference in survival between UPSC, CC,
and G3EC in stage IA disease (90, 87, and 94%; P¼0.28).
Using a Cox proportional hazards model, demographic
and clinico-pathologic prognostic factors were investigated as
independent predictors of survival after adjusting for contributing
factors such as age, race, stage, histology, and radiotherapy.
On multivariate analysis, advanced stage disease (Po0.001),
aggressive histologic cell types (UPSC and CC, Po0.001),
and older age at diagnosis (Po0.001) were all independent
predictors of poorer survival (Table 2). However, race
(P¼0.888) and radiotherapy (P¼0.450) were not significant
independent prognostic factors.
DISCUSSION
In 1982, Hendrickson et al (1982) identified UPSC as a clinically
aggressive and morphologically distinct variant of endometrial
adenocarcinoma. Clear cell endometrial carcinoma was first
described in the English literature in 1957. Both cell types have a
predilection for distant spread and recurrence (Kay, 1957;
Silverberg and De Giorgi, 1973; Kurman and Scully, 1976; Abeler
et al, 1996). Over the last two decades, these histologic types have
been grouped together with grade 3 endometrioid cancers as high-
risk tumours. However, debate remains whether there is a
significant difference in prognosis between these high-risk
subtypes and more importantly, if these cell types should be
treated as separate disease entities (Munkarah, 2004).
This is one of the largest series that compares the clinico-
pathologic prognostic factors and outcomes of patients with UPSC
and CC vs G3EC. Previous reports have shown that UPSC is an
uncommon uterine cancer but accounts for a disproportionate
number of endometrial cancer deaths (Hendrickson et al, 1982;
Carcangiu and Chambers, 1995). Similarly, in our series, patients
with UPSC comprised of only 10% of corpus cancers in our study
but accounted for 39% of endometrial cancer deaths. When
compared to women diagnosed with G3EC, patients with UPSC
accounted for 5% less cases but 12% more deaths. The patients
with UPSC and CC were older with median ages at 70 and 68 years
compared to 66 years in patients with G3EC. Women with UPSC
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Figure 3 Kaplan–Meier disease-specific survival by histology and stage.
100
75
50
25
0
0 50 100 150 200
Time (months)
P
e
r
c
e
n
t
 
s
u
r
v
i
v
a
l
 
(
%
)
Stage I−IV (P<0.0001) 
UPSC−Uterine papillary serous carcinoma
CC−Clear cell carcinoma
G3EC−Grade 3 endometrioid carcinoma 
G3EC
CC
UPSC
Figure 2 Kaplan–Meier disease-specific survival by histology.
Table 2 Multivariate analysis
Factors Hazard ratio 95% confidence interval P-value
Stage of disease 2.05 1.93–2.17 Po0.001
Histology
a 1.22 1.11–1.35 Po0.001
Age at diagnosis
b 1.03 1.03–1.04 Po0.001
Race
c 1.00 0.92–1.11 P¼0.888
Adjuvant radiotherapy 0.99 0.93–1.03 P¼0.450
aUterine papillary serous carcinoma vs clear cell carcinoma vs grade 3 endometrioid
carcinoma.
bAs a continuous variable.
cWhites vs Blacks vs Asians.
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sand/or CC have been described as type II corpus cancers that are
associated with older age (Bokhman, 1983). Although prior reports
have consistently demonstrated older age in patients with UPSC
and CC compared to endometrioid uterine cancers, this current
study is one of first series with sufficient numbers of patients to
show a statistically significant increase in age between the high-
risk histologies (Abeler and Kjorstad, 1991; Carcangiu and
Chambers, 1995; Matthews et al, 1997).
In this current series, the percent of patients with disease spread
beyond the uterus (stage II–IV) at the time of diagnosis was 64, 50,
and 40% for UPSC, CC, and G3EC, respectively (Po0.001). These
findings suggest that the poorer prognosis associated with these
histologies may be due to advanced disease at the time of
diagnosis. In a single institution report of 136 patients, Boruta et al
(2004) also found that patients with UPSC were more likely than
those with G3EC to present with extrauterine disease (OR¼2.2;
95% CI¼1.1–4.5). Additionally, Cirisano et al, also reported a
higher likelihood of upstaging and finding gross metastases among
UPSC and CC tumours compared to G3EC controlled for
comprehensiveness of surgical staging (Cirisano et al, 1999,
2000). Similar to our series, these reports point towards the more
aggressive behaviour of UPSC and CC compared to G3EC. In this
current report, we showed that the poorer prognosis of UPSC and
CC is not completely explained by the more advanced stage of
disease at presentation because the worse prognosis of these cell
types holds even after controlling for stage at presentation
(Figure 3).
Other prognostic factors that may impact survival include
complete surgical staging and extent of lymph node dissection
(Creasman et al, 1987; Chan et al, 2003; Huh et al, 2003). All
patients in this study underwent surgical staging based on FIGO
criteria and the majority of patients with early stage disease had a
lymph node assessment. Previous studies have demonstrated a
survival benefit associated with a thorough lymphadenectomy, we
proposed to determine if the extent of lymph node dissection may
have contributed to the better survival of those with G3EC. Our
data showed that the median number of nodes resected between
UPSC, CC, and G3EC patients were not statistically different, but
UPSC patients continued to have a poorer prognosis. Therefore,
using node count as a surrogate, it does not appear that stage
migration or an inequality in the extent of surgery contributed to
the poorer prognosis of UPSC or CC. Most importantly, higher-
risk histologies (UPSC and CC) remained as independent
prognostic factors for poorer survival in multivariate analysis.
Previous studies have also investigated the prognostic difference
between the high-risk histological types and found similar results.
In a series of 139 patients with early stage disease, those with UPSC
had a progression-free and overall survival that were significantly
worse than those with G3EC (35 vs 82%, P¼0.03 for progression-
free and 43 vs 89%, P¼0.02 for overall survival) (Boruta et al,
2004). Similarly, Cirisano et al, evaluated survival analyses in
stage I–II patients and demonstrated a worse 5-year survival in
those with UPSC and CC compared to endometrioid carcinoma
(56 vs 86%; P¼0.11). On the other hand, Alektiar et al (2002)
did not find a survival difference between these histologic
cell types; however, only 28% of patients in his series underwent
a comprehensive surgical staging procedure. More recently,
Creasman et al, performed a large population-based analysis
of 523 stage I patients with high-risk cell types from the
FIGO database. Although these authors did not find a survival
difference in those with stage IA and IB disease, the survival
of women with stage IC was poorer in those with UPSC compared
with CC or G3EC (Creasman et al, 2004). In our series, we
showed a worsened survival in those with stage IB and IC
UPSC compared to G3EC. However, similar to Creasman’s series,
we were unable to demonstrate a statistically significant difference
between those with stage IA disease. Table 3 summarises prior
studies that have evaluated the 5-year survival of high-risk
histologies.
As with other large population-based series, our report was
limited by a lack of central pathology review. To determine if there
are significant discrepancies between registry and referral
pathologists, Piver et al (2000), reviewed slides from a large
cancer registry and found only 1% of cases had major differences
with regard to either site of origin or histopathologic type.
Similarly, Tyler et al (1991) performed slide reviews on 477 women
diagnosed with ovarian cancer and compared the diagnoses of
pathologists contributing to tumour registries affiliated with the
SEER program to an expert panel of three gynecologic pathologists
and found and overall agreement of 97%.
Another shortcoming of this study is the lack of information
regarding adjuvant chemotherapy. Nevertheless, even in smaller
single institution reports, the treatment of patients with UPSC and
CC differed significantly. Recently, McMeekin et al (2005)
performed an analysis of 1203 patients diagnosed with advanced
or recurrent UPSC, CC, and endometrioid uterine cancers from the
Gynecologic Oncology Group, and found that the responses to
chemotherapy between these histologic cell types did not differ.
However, histology remained as an important prognostic factor.
More specifically, the relative hazard ratio for UPSC and CC was
1.20 (1.02–1.40; P¼0.03) and 1.51 (1.1–2.1; P¼0.01), respec-
tively. Thus, even though we were unable to obtain information
regarding adjuvant chemotherapy in our study, it appears that the
use of chemotherapy cannot completely explain the survival
differences observed in the histologic groups. Furthermore, the
survival differences between these histologic cell types persist even
in those with early stage disease where adjuvant chemotherapy is
typically not employed. Another potential concern is that women
with UPSC in our study received less adjuvant radiotherapy
compared to CC and G3EC patients. Although this difference in
Table 3 Studies comparing the survival of women diagnosed with high-risk corpus cancers
5-year survival rates
Year n Stage UPSC (%) CC (%) UPSC+CC (%) G3EC (%) P-value
Carcangiu (Carcangiu and Chambers, 1995) 1995 76 I–II 40 68% 0.03
Cirisano (Cirisano et al, 2000) 2000 81 I–II — — 56 71 0.11
Alektiar (Alektiar et al, 2002) 2002 83 I–II — — 79 71 0.3
Halperin (Halperin et al, 2002) 2002 64 I–IV 62.5 — — 80
b 40.05
Boruta (Boruta et al, 2004) 2004 96 I–IV 41
a —— 7 5 o0.01
Creasman (Creasman et al, 2004) 2004 532 I 72 79 — 75 —
Hamilton 2005 2595 I–II 74 82 86 o0.0001
1585 III–IV 33 40 53 o0.0001
aGreater than 50% UPSC.
bIncludes grade 2 endometrioid carcinoma (n¼19) and grade 3 endometrioid carcinoma (n¼11). UPSC¼uterine papillary serous carcinoma.
CC¼clear cell carcinoma. G3EC¼grade 3 endometrioid carcinoma.
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patients, we showed that radiotherapy did not impact the survival
of our patients in multivariate analysis. Moreover, it is possible
that many of the UPSC patients underwent chemotherapy rather
than radiotherapy given that UPSC has a predilection for distant
metastases (Cirisano et al, 1999; Huh et al, 2003; Hamilton et al,
2005). Despite the limited and incomplete information available
on adjuvant treatment, our data reflect the lack of community
standard which perpetuates inconsistency of approach and
variation both within and between treatment centres.
The data from this population-based study allows one to
generate interesting hypotheses. The strength in the large number
of patients in this series may overcome potential limitations such
as the lack of central pathology review and selection biases
associated with large population-based analyses. Nevertheless, the
demographic and clinico-pathologic data obtained from this report
are a true reflection of the trends and outcomes of US women
diagnosed with poor histologic uterine carcinoma who receive
medical care from community hospitals based on diagnoses from
contributing pathologists rather than from gynecologic patholo-
gists in academic centres.
Our data suggests that UPSC and CC are histologically distinct
tumours with aggressive tumour biology. Although current
treatment modalities for these high-risk cell types have resulted
in similar response rates compared to endometrioid tumours,
UPSC and CC are discrete histologic subtypes that should be
segregated from the more common endometrioid corpus cancers.
In this manner, we can effectively design tailored therapies that
may improve the outcomes of women diagnosed with these
aggressive cancers.
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